Dr. Salman Ahmed

Therapeutic potential of naringin in neurological disorders

• Authors Details :  
• Salman Ahmed,  
• Haroon Khan,  
• Michael Aschner,  
• Muhammad Mohtasheemul Hasan,  
• Sherif T.s.hassan

Journal title : Food and Chemical Toxicology

Publisher : Elsevier BV

Print ISSN : 0278-6915

Page Number : 110646

Journal volume : 132

47 Views Reviews Article

Neurological illnesses are multifactorial incurable debilitating disorders that may cause neurodegeneration. These diseases influence approximately 30 million people around the world. Despite several therapies, effective management of such disorders remains a global challenge. Thus, natural products might offer an alternative medicine for treating neurological disorders. Polyphenols, such as curcumin, resveratrol, myricetin, mangiferin, and naringin (NRG), have been shown to possess promising potential in treating neurogenerative illness. In this review, we have targeted the therapeutic potential of naringin as a neuroprotective agent. The overall neuroprotective effects and possible underlying mechanisms related to NRG are discussed. In light of the strong evidence for the neuropharmacological efficacy of NRG in various experimental paradigms, it is concluded that this molecule should be further considered and studied as a potential candidate for neurotherapeutics, focusing on mechanistic and clinical trials to ascertain its efficacy.

Article DOI & Crossmark Data

DOI : https://doi.org/10.1016/j.fct.2019.110646

Article Subject Details

• Medicine
• Neuroendocrinology
• Neurology
• Neuropharmacology
• Neuroscience
• Pharmacognosy
• Pharmacology

Article Keywords Details

• Antiapoptotic
• Antineuroinflammation
• Antioxidant
• Naringin
• Polyphenols

Article File

Full Text PDF

---

---

Article References

• (1). 10.1016/j.lfs.2010.04.011
• (2). 10.3389/fnmol.2015.00035
• (3). 10.1016/j.febslet.2011.07.046
• (4). 10.1007/s13105-011-0142-y
• (5). 10.1007/s13277-015-4230-4
• (6). 10.1002/cber.19280610713
• (7). 10.1007/s11064-014-1326-y
• (8). 10.1016/j.biopha.2018.10.055
• (9). 10.1055/a-0575-3730
• (10). 10.1161/STROKEAHA.108.527705
• (11). 10.1055/s-0034-1368351
• (12). 10.1155/2017/6031478
• (13). 10.1007/s00394-010-0117-8
• (14). 10.1016/j.fitote.2013.11.003
• (15). 10.1155/2018/4067597
• (16). 10.1016/j.fct.2018.08.028
• (17). 10.1007/s12035-018-1027-7
• (18). 10.1016/S0944-7113(98)80018-4
• (19). 10.1016/j.ejphar.2009.06.056
• (20). 10.1371/journal.pone.0012399
• (21). 10.1016/j.yebeh.2014.09.058
• (22). 10.1002/dvdy.20512
• (23). 10.1016/j.neuroscience.2012.07.060
• (24). 10.1139/cjpp-2015-0035
• (25). 10.1007/s10571-012-9827-1
• (26). 10.1016/j.brainresbull.2016.12.008
• (27). 10.1021/jf035079g
• (28). 10.1159/000076349
• (29). 10.3892/br.2014.267
• (30). 10.5607/en.2014.23.2.124
• (31). 10.3109/03639040903140589
• (32). 10.1016/j.fitote.2012.01.010
• (33). 10.1007/s12253-013-9702-5
• (34). 10.3736/jcim20121223
• (35). 10.1055/s-2004-815449
• (36). 10.3109/10717544.2013.878003
• (37). 10.3109/03639045.2014.902466
• (38). 10.1016/j.autrev.2019.05.001
• (39). 10.1016/j.coph.2011.10.007
• (40). 10.4196/kjpp.2009.13.4.281
• (41). 10.1089/jmf.2016.3712
• (42). 10.4103/1673-5374.213694
• (43). 10.1016/j.yebeh.2018.10.006
• (44). 10.1016/j.yebeh.2017.07.011
• (45). 10.1128/MCB.01428-09
• (46). 10.1007/s11010-015-2525-9
• (47). 10.1089/jmf.2009.1251
• (48). 10.1016/j.fct.2009.11.043
• (49). 10.1016/j.bbr.2009.08.028
• (50). 10.1016/j.compbiomed.2018.05.012
• (51). 10.1007/s10570-013-9970-y
• (52). 10.1007/s11064-018-2488-9
• (53). 10.1016/j.bbrc.2014.08.117
• (54). 10.1080/1061186X.2016.1184668
• (55). 10.1016/j.neuropharm.2013.11.026
• (56). 10.1002/path.4449
• (57). 10.1016/j.bbrc.2015.10.152
• (58). 10.1211/jpp.58.9.0009
• (59). 10.1016/j.bcp.2004.09.018
• (60). 10.1016/j.canlet.2018.07.018
• (61). 10.1016/j.phrs.2017.10.008
• (62). 10.3390/antiox7080109
• (63). 10.1080/09168451.2018.1456320
• (64). 10.1016/j.jep.2008.02.015
• (65). 10.1016/j.fct.2008.09.056
• (66). 10.3109/00207454.2013.785542
• (67). 10.1016/j.abb.2011.11.026
• (68). 10.1016/j.brainresbull.2016.04.020
• (69). 10.1016/j.neuroscience.2012.09.026
• (70). 10.1016/j.tox.2007.01.006
• (71). 10.1016/j.biopha.2017.08.028
• (72). 10.1016/j.biopha.2016.10.080
• (73). 10.1016/j.fct.2012.07.033
• (74). 10.2174/1381612822666160530150936
• (75). 10.1371/journal.pone.0082577
• (76). 10.1016/j.neuroscience.2012.10.041
• (77). 10.1016/j.pharmthera.2018.09.009
• (78). 10.4103/1673-5374.202923
• (79). 10.1007/s11064-012-0756-7
• (80). 10.1016/j.pbb.2014.11.002
• (81). 10.1016/j.brainres.2012.08.036
• (82). 10.1093/jn/136.6.1477
• (83). 10.3892/mmr.2014.1940
• (84). 10.1371/journal.pone.0018033
• (85). 10.1159/000453580
• (86). 10.1021/acs.jafc.8b02696
• (87). 10.1016/j.bcp.2013.03.018
• (88). 10.18632/oncotarget.25175
• (89). 10.1016/j.biopha.2017.07.072
• (90). 10.3736/jcim20111115
• (91). 10.1039/C4RA04920A
• (92). 10.1208/s12249-016-0537-8
• (93). 10.1016/j.pbb.2012.03.013
• (94). 10.1007/s10571-015-0201-y
• (95). 10.3892/ijmm.2017.2904
• (96). 10.1016/j.cbi.2015.10.010
• (97). 10.1142/S0192415X07005156
• (98). 10.1002/jor.20279
• (99). 10.1007/s12035-014-9042-9
• (100). 10.12659/MSM.902396
• (101). 10.1248/bpb.b12-00451
• (102). 10.1016/j.carbpol.2013.07.010
• (103). 10.1007/s10072-013-1594-3
• (104). 10.3389/fnagi.2018.00169
• (105). 10.1007/s11095-008-9791-0
• (106). 10.1016/j.cbi.2015.04.003
• (107). 10.1016/j.pnpbp.2010.06.024
• (108). 10.1016/j.pnpbp.2012.06.009
• (109). 10.1016/j.pnpbp.2013.10.002
• (110). 10.1016/j.bmcl.2012.10.130
• (111). 10.1007/s10753-014-0022-z
• (112). 10.1080/10715760500233113
• (113). 10.1021/je501004g

---

More Article by Dr. Salman Ahmed